Literature DB >> 18541331

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Greg M Thurber1, Michael M Schmidt, K Dane Wittrup.   

Abstract

Antibodies have proven to be effective agents in cancer imaging and therapy. One of the major challenges still facing the field is the heterogeneous distribution of these agents in tumors when administered systemically. Large regions of untargeted cells can therefore escape therapy and potentially select for more resistant cells. We present here a summary of theoretical and experimental approaches to analyze and improve antibody penetration in tumor tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541331      PMCID: PMC2820307          DOI: 10.1016/j.addr.2008.04.012

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  156 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

3.  Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

Authors:  Theresa A John; Stephen M Vogel; Chinnaswamy Tiruppathi; Asrar B Malik; Richard D Minshall
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-01       Impact factor: 5.464

4.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

Authors:  Christilyn P Graff; K Dane Wittrup
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

5.  Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins.

Authors:  Cornelia Halin; Uwe Niesner; Maria Elena Villani; Luciano Zardi; Dario Neri
Journal:  Int J Cancer       Date:  2002-11-10       Impact factor: 7.396

6.  An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.

Authors:  Samu Melkko; Cornelia Halin; Laura Borsi; Luciano Zardi; Dario Neri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

7.  Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.

Authors:  Rosana B Michel; Rita Ochakovskaya; M Jules Mattes
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

8.  Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin.

Authors:  Manuel J Koppe; Annemieke C Soede; Wikke Pels; Wim J G Oyen; David M Goldenberg; Robert P Bleichrodt; Otto C Boerman
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

9.  STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.

Authors:  Kristian Pietras; Michael Stumm; Martine Hubert; Elisabeth Buchdunger; Kristofer Rubin; Carl-Henrik Heldin; Paul McSheehy; Markus Wartmann; Arne Ostman
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

10.  Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells.

Authors:  C de L Davies; D A Berk; A Pluen; R K Jain
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more
  209 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

2.  Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells.

Authors:  Rick K Huang; Nicole F Steinmetz; Chi-Yu Fu; Marianne Manchester; John E Johnson
Journal:  Nanomedicine (Lond)       Date:  2011-01       Impact factor: 5.307

3.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

Review 4.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

5.  Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.

Authors:  Cornelius Cilliers; Bruna Menezes; Ian Nessler; Jennifer Linderman; Greg M Thurber
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

6.  In vivo fluorescence imaging of hepatocellular carcinoma xenograft using near-infrared labeled epidermal growth factor receptor (EGFR) peptide.

Authors:  Z Li; Q Zhou; J Zhou; X Duan; J Zhu; T D Wang
Journal:  Biomed Opt Express       Date:  2016-08-01       Impact factor: 3.732

7.  Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Authors:  Emily Wonder; Lorena Simón-Gracia; Pablo Scodeller; Ramsey N Majzoub; Venkata Ramana Kotamraju; Kai K Ewert; Tambet Teesalu; Cyrus R Safinya
Journal:  Biomaterials       Date:  2018-03-02       Impact factor: 12.479

8.  Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.

Authors:  Greg M Thurber; Thomas Reiner; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  Mol Cancer Ther       Date:  2014-02-19       Impact factor: 6.261

9.  Potato virus X as a novel platform for potential biomedical applications.

Authors:  Nicole F Steinmetz; Marianne E Mertens; Rebecca E Taurog; John E Johnson; Ulrich Commandeur; Rainer Fischer; Marianne Manchester
Journal:  Nano Lett       Date:  2010-01       Impact factor: 11.189

10.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Authors:  Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson
Journal:  AAPS J       Date:  2016-05-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.